BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 18612161)

  • 1. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances using anti-CTLA-4 for the treatment of melanoma.
    Sarnaik AA; Weber JS
    Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of melanoma: present options and future promises.
    Rotte A; Bhandaru M; Zhou Y; McElwee KJ
    Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for melanoma.
    Kim CJ; Dessureault S; Gabrilovich D; Reintgen DS; Slingluff CL
    Cancer Control; 2002; 9(1):22-30. PubMed ID: 11907463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells in the immunotherapy of melanoma.
    Ouyang Z; Wu H; Li L; Luo Y; Li X; Huang G
    Tumour Biol; 2016 Jan; 37(1):77-85. PubMed ID: 26515336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma: an update.
    Homsi J; Grimm JC; Hwu P
    Surg Oncol Clin N Am; 2011 Jan; 20(1):145-63. PubMed ID: 21111964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
    Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.